$1.58 +0.08 (%) Synthetic Biologics Inc - AMEX

Dec. 19, 2014 | 03:55 PM

Partner Headlines

  1. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  2. Earnings Scheduled For November 14, 2014

    Benzinga | Nov. 14, 2014 | 05:05AM EST
  3. Synthetic Biologics Issues UCLA Report of Prelim. Positive Topline Efficacy, Safety Results from Phase II Study of Trimesta

    Benzinga | Apr. 29, 2014 | 15:46PM EST
  4. Morning Market Movers

    Benzinga | Mar. 31, 2014 | 09:40AM EST
  5. Earnings Scheduled For March 31, 2014

    Benzinga | Mar. 31, 2014 | 05:03AM EST
  6. Intrexon: Living Better Through Synthetic Biology?

    IBD | Jan. 28, 2014 | 14:03PM EST
  7. Morning Market Losers

    Benzinga | Dec. 12, 2013 | 09:59AM EST
  8. Synthetic Biologics Prices 11.5M Share Offering at $1.00/Share

    Benzinga | Dec. 11, 2013 | 21:14PM EST
  9. Synthetic Biologics, Intrexon Initiate Development of Novel Biologics for a Subset of Patients Suffering from IBS

    Benzinga | Dec. 9, 2013 | 16:29PM EST
  10. Synthetic Biologics Enters License Agreement with Cedars-Sinai Medical Center to Develop New Treatments for IBS, Obesity, Diabetes

    Benzinga | Dec. 7, 2013 | 20:06PM EST
  11. Intrexon IPO Prices High After Upsizing; Stock Soars

    IBD | Aug. 8, 2013 | 12:28PM EST
  12. Synodon Inc. - A Breakthrough Technology For Pipeline Safety

    GuruFocus | Jan. 28, 2013 | 10:46AM EST
  13. Synthetic Biologics Inc (SYN) CEO Jeffrey Scott Riley buys 2,900 Shares

    GuruFocus | Jan. 7, 2013 | 10:36AM EST
  14. Synthetic Biologics Inc (SYN) CEO Jeffrey Scott Riley buys 2,000 Shares

    GuruFocus | Jan. 4, 2013 | 11:08AM EST
  15. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman

    Benzinga | May. 11, 2012 | 01:02AM EST
  16. Adeona Becomes Synthetic Biologics

    Benzinga | Feb. 16, 2012 | 01:14AM EST
Trading Center